Form 4: PTC Therapeutics Officer Sells Shares for Tax Obligations

PTC Therapeutics' Chief Technical Operations Officer, Neil Gregory Almstead, sold shares to cover tax liabilities from RSU vesting.

Summary

• Neil Gregory Almstead, Chief Technical Operations Officer of PTC Therapeutics, Inc. (PTCT), reported a sale of company common stock.
• The transactions occurred on January 8, 2026, and were made pursuant to a Rule 10b5-1 plan.
• A total of 881 shares were sold directly at a price of $76.45 per share.
• An additional 59 shares were sold indirectly by Almstead's spouse at the same price of $76.45 per share.
• These sales were "sell to cover" transactions to satisfy tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
• The RSUs stemmed from grants made on January 7, 2022, specifically 3,600 RSUs from a 14,400 grant and 195 RSUs from a 780 grant.
• Following these transactions, Almstead directly beneficially owns 115,196 shares and indirectly owns 6,791 shares through his spouse.

Sentiment

Score: 5

Explanation: The transaction is a routine 'sell to cover' for tax purposes upon RSU vesting, indicating neither positive nor negative discretionary sentiment from the insider.

Future Outlook

NA

Industry Context

This is a routine insider transaction for tax purposes and does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine, non-discretionary sale to cover tax obligations related to RSU vesting, which is a common practice for executive compensation.

Key Dates

Keywords

PTC Therapeutics, PTCT, Form 4, Insider Trading, Stock Sale, RSU Vesting, Tax Withholding, Executive Compensation, Neil Gregory Almstead